Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Rese-cel (formerly CABA-201) in Myositis . The expected timing is based on the latest available company guidance and may change.
06/03/26:- RESET-Myositis registrational DM/ASyS topline data expected Mid-2027. Myositis BLA submission planned 2H 2027. 08/13/26:- EULAR 2026 Phase 1/2 data updated. RESET-Myositis registrational data will be reported Mid-2027; BLA submission will follow in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.